Company logo

EXAS - Exact Sciences Corporation

NASDAQ -> Healthcare -> Diagnostics & Research
Madison, United States
Type: Equity

EXAS price evolution
EXAS
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $582.74 $530.18 $347.49 $605.38
Short term investments $416.6 $304.61 $172.27
Net receivables $264.82 $263.87 $240.58 $203.62
Inventory $136.99 $127.37 $128.53 $127.47
Total current assets $1533.12 $1452.49 $1120.27 $1194.37
Long term investments
Property, plant & equipment $834.38 $842.89 $844.06 $842.06
Goodwill & intangible assets $4210.45 $4233.91 $4257.52
Total noncurrent assets $5220.81 $5256.05 $5276.97
Total investments $416.6 $304.61 $172.27
Total assets $6748.57 $6673.3 $6376.32 $6471.33
Current liabilities
Accounts payable $97.65 $52.98 $60.5 $78.82
Deferred revenue
Short long term debt $276.02 $326.04 $79.38
Total current liabilities $723.66 $668.64 $685.11 $514.7
Long term debt $2334.29 $2485.61 $2229.21 $2475.35
Total noncurrent liabilities $2812.29 $2558.59 $2811.33
Total debt $2761.63 $2555.24 $2554.72
Total liabilities $3538.06 $3480.93 $3243.7 $3326.03
Shareholders' equity
Retained earnings -$3633.45 -$3595.21 -$3579.4 -$3469.18
Other shareholder equity $1.8 -$0.94 -$0.5 $1.43
Total shareholder equity $3192.36 $3132.62 $3145.3
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $605.38 $178.17 $315.47 $1491.29
Short term investments $172.27 $389.56 $715 $348.7
Net receivables $203.62 $158.04 $216.65 $233.19
Inventory $127.47 $118.26 $104.99 $92.27
Total current assets $1194.37 $982.26 $1426.24 $2198.59
Long term investments $29.1
Property, plant & equipment $842.06 $861.96 $754.47 $576.63
Goodwill & intangible assets $4257.52 $4302.28 $4429.58 $2086.1
Total noncurrent assets $5276.97 $5244.62 $5258.65 $2726.5
Total investments $172.27 $389.56 $715 $348.7
Total assets $6471.33 $6226.87 $6684.88 $4925.09
Current liabilities
Accounts payable $78.82 $74.92 $67.83 $35.71
Deferred revenue
Short long term debt $79.38 $28.37 $19.71 $268.27
Total current liabilities $514.7 $412.75 $517.07 $575.84
Long term debt $2475.35 $2243.51 $2362.4 $1464.18
Total noncurrent liabilities $2811.33 $2770.96 $2780.18 $1525.76
Total debt $2554.72 $2446.87 $2382.11 $1732.44
Total liabilities $3326.03 $3183.71 $3297.25 $2101.6
Shareholders' equity
Retained earnings -$3469.18 -$3265.03 -$2641.52 -$1968.29
Other shareholder equity $1.43 $0.05 -$1.44 $0.53
Total shareholder equity $3145.3 $3043.16 $3387.64 $2823.49
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $699.26 $637.52 $646.88
Cost of revenue $189.85 $170.1 $171.87
Gross Profit $509.42 $467.42 $475.02
Operating activities
Research & development $120.88 $110.61 $114.92
Selling, general & administrative $387.13 $435.48 $411.03
Total operating expenses $535.67 $574.12 $542.86
Operating income -$26.26 -$106.69 -$67.84
Income from continuing operations
EBIT -$14.46 -$100.48 -$42.51
Income tax expense $1.46 $1.81 -$0.61
Interest expense -$0.11 $7.94 $7.87
Net income
Net income -$15.81 -$110.23 -$49.77
Income (for common shares) -$15.81 -$110.23 -$49.77
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $2499.77 $2084.28 $1767.09 $1491.39
Cost of revenue $654.25 $574.39 $458.76 $354.32
Gross Profit $1845.52 $1509.88 $1308.33 $1137.07
Operating activities
Research & development $425.88 $393.42 $385.65 $554.05
Selling, general & administrative $1620.29 $1583.32 $1663.15 $1071.63
Total operating expenses $2060.53 $2103.4 $2164.01 $1905.09
Operating income -$215.01 -$593.51 -$855.68 -$768.02
Income from continuing operations
EBIT -$182.3 -$612.94 -$823.9 -$761.12
Income tax expense $2.4 -$9.06 -$246.88 -$8.57
Interest expense $19.45 $19.63 $18.61 $95.98
Net income
Net income -$204.15 -$623.51 -$595.63 -$848.53
Income (for common shares) -$204.15 -$623.51 -$595.63 -$848.53
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$15.81 -$110.23 -$49.77
Operating activities
Depreciation $59.99 $60.99 $61.15
Business acquisitions & disposals -$12.21
Stock-based compensation $56.55 $60.37 $58.58
Total cash flows from operations $107.06 -$82.31 $69.55
Investing activities
Capital expenditures -$35.87 -$37.65 -$34.92
Investments -$111.26 -$133.58 -$20.14
Total cash flows from investing -$400.28 -$147.13 -$171.44 -$66.77
Financing activities
Dividends paid
Sale and purchase of stock $19.45 -$1.41 $12.3
Net borrowings $216.75
Total cash flows from financing $221.38 $224.6 -$3 $10.04
Effect of exchange rate $0.43 -$0.31 -$1.14 $1.95
Change in cash and equivalents -$15.01 $184.23 -$257.89 $14.77
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$204.15 -$623.51 -$595.63 -$848.53
Operating activities
Depreciation $234.5 $226.2 $206.17 $179.08
Business acquisitions & disposals -$52.91 -$57.51 -$575.85 -$434.03
Stock-based compensation $231.31 $206.82 $334.02 $152.91
Total cash flows from operations $156.12 -$223.56 -$102.24 $136.48
Investing activities
Capital expenditures -$124.19 -$189.46 -$135.77 -$64.35
Investments $226.53 $321.59 -$369.73 -$203.28
Total cash flows from investing $49.68 $74.07 -$1082.09 -$702.04
Financing activities
Dividends paid
Sale and purchase of stock $31.54 $32.02 $37.51 $907.13
Net borrowings $137.98 $50 -$23.75 $975.49
Total cash flows from financing $159.77 $76.48 $8.47 $1879.62
Effect of exchange rate $1.32 $0.03 $0.02
Change in cash and equivalents $366.88 -$72.98 -$1175.83 $1314.07
News
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
Zacks · via Yahoo Finance 8 Jan 2025
Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right...
Insider Monkey · via Yahoo Finance 19 Nov 2024
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
Zacks · via Yahoo Finance 18 Nov 2024
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter
Insider Monkey · via Yahoo Finance 11 Nov 2024
Exact Sciences Corporation (EXAS): A Buzzing AI Health Stock to Add to Your...
Insider Monkey · via Yahoo Finance 4 Oct 2024
Should You Believe in the Growth Potential of Exact Sciences Corporation (EXAS)?
Insider Monkey · via Yahoo Finance 24 Aug 2024
Exact Sciences Corporation (EXAS) Slipped Over Investors’ Concerns
Insider Monkey · via Yahoo Finance 24 Jul 2024
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Zacks via Yahoo Finance 28 May 2024
Hedge Funds are Bullish on This Cancer Stock
Insider Monkey via Yahoo Finance 28 May 2024
Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the...
Insider Monkey · via Yahoo Finance 23 May 2024
Fundamentals
Market cap $10.37B
Enterprise value N/A
Shares outstanding 185.05M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share 3.15
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.06
Net debt/EBITDA N/A
Current ratio 2.12
Quick ratio 1.93